Covered recipient · General Payments record
TRISHA WISE-DRAPER
Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2019 · Entire year
$262.13
3 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2019 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $197.13 | 2 |
| Education | $65.00 | 1 |
By paying entity
PY2019 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| IsoRay, Inc | $132.02 | 1 |
| AstraZeneca Pharmaceuticals LP | $65.11 | 1 |
| EISAI INC. | $65.00 | 1 |
Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
TRISHA WISE-DRAPER
NPI 1306162367 · CMS profile ID 1348174
Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology
CINCINNATI, OH
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1306162367?year=2019&recipient=provider#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- TRISHA WISE-DRAPER, NPI 1306162367, CMS profile ID 1348174. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1306162367?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
- APA 7
- IndustryPayments. (2026). TRISHA WISE-DRAPER, NPI 1306162367, CMS profile ID 1348174. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1306162367?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
- Bluebook
- TRISHA WISE-DRAPER, NPI 1306162367, CMS profile ID 1348174, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1306162367?year=2019&recipient=provider#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2019
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30
3 matching records · $262.13 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 1–3 of 3.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| EISAI INC. | $65.00 | 10/22/2019 | Education | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 697047829 | CMS |
| AstraZeneca Pharmaceuticals LP | $65.11 | 09/28/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 685248533 | CMS |
| IsoRay, Inc | $132.02 | 04/30/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 708194935 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2023, 2024, 2025
Source files and profile matching
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $1,091,344.57 | 191 |
| PY2024 | Recipient | $1,142.00 | 1 |
| PY2024 | Principal investigator | $1,113,643.03 | 103 |
| PY2023 | Principal investigator | $647,553.50 | 123 |
| PY2022 | Principal investigator | $951,903.86 | 101 |
| PY2021 | Principal investigator | $1,602,672.00 | 113 |
| PY2020 | Recipient | $2,270.00 | 3 |
| PY2020 | Principal investigator | $2,351,551.68 | 45 |
| PY2019 | Principal investigator | $1,957,016.08 | 55 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2024
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
104 records in PY2024
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Ares Trading SA | $1,008.00 | 12/20/2024 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI PHYSICIANS | An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies | No dispute reported | 06/30/2026 | 1133562736 |
| Principal investigator 1 | Ares Trading SA | $948.00 | 12/20/2024 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI PHYSICIANS | An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies | No dispute reported | 06/30/2026 | 1133562740 |
| Principal investigator 1 | Ares Trading SA | $734.40 | 12/20/2024 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI PHYSICIANS | An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies | No dispute reported | 06/30/2026 | 1133562749 |
| Principal investigator 1 | Ares Trading SA | $1,008.00 | 12/20/2024 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI PHYSICIANS | An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies | No dispute reported | 06/30/2026 | 1133562755 |
| Principal investigator 1 | Ares Trading SA | $1,008.00 | 12/20/2024 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI PHYSICIANS | An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies | No dispute reported | 06/30/2026 | 1133562767 |
| Principal investigator 1 | Ares Trading SA | $1,008.00 | 12/20/2024 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI PHYSICIANS | An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies | No dispute reported | 06/30/2026 | 1133562773 |
| Principal investigator 1 | Ares Trading SA | $948.00 | 12/20/2024 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI PHYSICIANS | An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies | No dispute reported | 06/30/2026 | 1133562793 |
| Principal investigator 1 | Ares Trading SA | $948.00 | 12/20/2024 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI PHYSICIANS | An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies | No dispute reported | 06/30/2026 | 1133562807 |
| Principal investigator 1 | Ares Trading SA | $948.00 | 12/20/2024 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI PHYSICIANS | An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies | No dispute reported | 06/30/2026 | 1133562812 |
| Principal investigator 1 | Ares Trading SA | $948.00 | 12/20/2024 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI PHYSICIANS | An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies | No dispute reported | 06/30/2026 | 1133562821 |
| Principal investigator 1 | Ares Trading SA | $948.00 | 12/20/2024 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI PHYSICIANS | An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies | No dispute reported | 06/30/2026 | 1133562828 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $22,401.00 | 12/09/2024 | Non-covered Recipient Entity University Of Cincinnati | Phase I/II FIH Monotherapy/Nivo Combination | No dispute reported | 06/30/2026 | 1123480676 |
| Principal investigator 1 | Janssen Research & Development, LLC | $251,455.90 | 12/02/2024 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI | Phase II study to evaluate amivantamab in recurrent and metastatic adenoid cystic carcinoma | No dispute reported | 06/30/2026 | 1078999276 |
| Principal investigator 1 | Ares Trading SA | $948.00 | 11/25/2024 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI PHYSICIANS | An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies | No dispute reported | 06/30/2026 | 1133562715 |
| Principal investigator 1 | Ares Trading SA | $948.00 | 11/25/2024 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI PHYSICIANS | An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies | No dispute reported | 06/30/2026 | 1133562719 |
| Principal investigator 1 | Ares Trading SA | $1,008.00 | 11/25/2024 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI PHYSICIANS | An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies | No dispute reported | 06/30/2026 | 1133562727 |
| Principal investigator 1 | Ares Trading SA | $272.40 | 11/25/2024 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI PHYSICIANS | An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies | No dispute reported | 06/30/2026 | 1133562752 |
| Principal investigator 1 | Ares Trading SA | $948.00 | 11/25/2024 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI PHYSICIANS | An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies | No dispute reported | 06/30/2026 | 1133562782 |
| Principal investigator 1 | Ares Trading SA | $948.00 | 11/25/2024 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI PHYSICIANS | An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies | No dispute reported | 06/30/2026 | 1133562790 |
| Principal investigator 1 | Ares Trading SA | $1,008.00 | 11/25/2024 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI PHYSICIANS | An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies | No dispute reported | 06/30/2026 | 1133562837 |
| Principal investigator 1 | Daiichi Sankyo Company LTD | $50,198.00 | 10/08/2024 | Non-covered Recipient Entity University Of Cincinnati | DS1055-A-J101 | No dispute reported | 06/30/2026 | 1075870271 |
| Recipient | Eli Lilly and Company | $1,142.00 | 09/24/2024 | Covered Recipient Physician | A MULTICENTER, RANDOMIZED, OPEN LABEL, PHASE 3 TRIAL COMPARING SELPERCATINIB TO PHYSICIANS CHOICE OF CABOZANTINIB OR VANDETANIB IN PATIENTS WITH PROGRESSIVE, ADVANCED, KINASE INHIBITOR NAIVE, RET MUTANT MEDULLARY THYROID CANCER (LIBRETTO 531) | No dispute reported | 06/30/2026 | 1137349789 |
| Principal investigator 1 | Coherus Biosciences Inc. | $51,382.00 | 09/20/2024 | Non-covered Recipient Entity University of Cincinnati | SRF114-101 | No dispute reported | 06/30/2026 | 1147273463 |
| Principal investigator 1 | Ares Trading SA | $597.60 | 09/19/2024 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY | An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies | No dispute reported | 06/30/2026 | 1133563046 |
| Principal investigator 1 | Ares Trading SA | $948.00 | 09/19/2024 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY | An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies | No dispute reported | 06/30/2026 | 1133563060 |
| Principal investigator 1 | Ares Trading SA | $948.00 | 09/19/2024 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY | An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies | No dispute reported | 06/30/2026 | 1133563067 |
| Principal investigator 1 | Ares Trading SA | $948.00 | 09/19/2024 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY | An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies | No dispute reported | 06/30/2026 | 1133563076 |
| Principal investigator 1 | Ares Trading SA | $948.00 | 09/19/2024 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY | An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies | No dispute reported | 06/30/2026 | 1133563084 |
| Principal investigator 1 | Ares Trading SA | $948.00 | 09/19/2024 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY | An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies | No dispute reported | 06/30/2026 | 1133563088 |
| Principal investigator 1 | Ares Trading SA | $948.00 | 09/19/2024 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY | An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies | No dispute reported | 06/30/2026 | 1133563095 |
| Principal investigator 1 | Ares Trading SA | $948.00 | 09/19/2024 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY | An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies | No dispute reported | 06/30/2026 | 1133563100 |
| Principal investigator 1 | Ares Trading SA | $948.00 | 09/19/2024 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY | An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies | No dispute reported | 06/30/2026 | 1133563111 |
| Principal investigator 1 | Ares Trading SA | $948.00 | 09/19/2024 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY | An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies | No dispute reported | 06/30/2026 | 1133563115 |
| Principal investigator 1 | Ares Trading SA | $948.00 | 09/19/2024 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY | An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies | No dispute reported | 06/30/2026 | 1133563120 |
| Principal investigator 1 | Ares Trading SA | $948.00 | 09/19/2024 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY | An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies | No dispute reported | 06/30/2026 | 1133563124 |
| Principal investigator 1 | Ares Trading SA | $948.00 | 09/19/2024 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY | An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies | No dispute reported | 06/30/2026 | 1133563135 |
| Principal investigator 1 | Ares Trading SA | $948.00 | 09/19/2024 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY | An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies | No dispute reported | 06/30/2026 | 1133563142 |
| Principal investigator 1 | Ares Trading SA | $948.00 | 09/19/2024 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY | An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies | No dispute reported | 06/30/2026 | 1133563151 |
| Principal investigator 1 | Ares Trading SA | $948.00 | 09/19/2024 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY | An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies | No dispute reported | 06/30/2026 | 1133563155 |
| Principal investigator 1 | Ares Trading SA | $948.00 | 09/19/2024 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY | An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies | No dispute reported | 06/30/2026 | 1133563164 |
| Principal investigator 1 | Ares Trading SA | $948.00 | 09/19/2024 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY | An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies | No dispute reported | 06/30/2026 | 1133563174 |
| Principal investigator 1 | Ares Trading SA | $948.00 | 09/19/2024 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY | An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies | No dispute reported | 06/30/2026 | 1133563181 |
| Principal investigator 1 | Ares Trading SA | $1,008.00 | 09/19/2024 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY | An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies | No dispute reported | 06/30/2026 | 1133563188 |
| Principal investigator 1 | Ares Trading SA | $1,008.00 | 09/19/2024 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY | An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies | No dispute reported | 06/30/2026 | 1133563190 |
| Principal investigator 1 | Ares Trading SA | $1,008.00 | 09/19/2024 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY | An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies | No dispute reported | 06/30/2026 | 1133563192 |
| Principal investigator 1 | Ares Trading SA | $1,008.00 | 09/19/2024 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY | An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies | No dispute reported | 06/30/2026 | 1133563194 |
| Principal investigator 1 | Ares Trading SA | $1,008.00 | 09/19/2024 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY | An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies | No dispute reported | 06/30/2026 | 1133563196 |
| Principal investigator 1 | Ares Trading SA | $1,008.00 | 09/19/2024 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY | An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies | No dispute reported | 06/30/2026 | 1133563198 |
| Principal investigator 1 | Ares Trading SA | $1,008.00 | 09/19/2024 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY | An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies | No dispute reported | 06/30/2026 | 1133563204 |
| Principal investigator 1 | Ares Trading SA | $1,008.00 | 09/19/2024 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY | An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies | No dispute reported | 06/30/2026 | 1133563213 |
| Principal investigator 1 | Ares Trading SA | $1,008.00 | 09/19/2024 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY | An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies | No dispute reported | 06/30/2026 | 1133563225 |
| Principal investigator 1 | Ares Trading SA | $1,008.00 | 09/19/2024 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY | An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies | No dispute reported | 06/30/2026 | 1133563234 |
| Principal investigator 1 | Ares Trading SA | $1,008.00 | 09/19/2024 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY | An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies | No dispute reported | 06/30/2026 | 1133563238 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,725.00 | 09/09/2024 | Non-covered Recipient Entity University Of Cincinnati | DS1055-A-J101 | No dispute reported | 06/30/2026 | 1086074140 |
| Principal investigator 1 | Daiichi Sankyo Company LTD | $4,725.00 | 09/06/2024 | Non-covered Recipient Entity University Of Cincinnati | DS1055-A-J101 | No dispute reported | 06/30/2026 | 1075870273 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 09/03/2024 | Non-covered Recipient Entity University Of Cincinnati | DS1055-A-J101 | No dispute reported | 06/30/2026 | 1086074132 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,430.00 | 09/03/2024 | Non-covered Recipient Entity University Of Cincinnati | DS1055-A-J101 | No dispute reported | 06/30/2026 | 1086074134 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,860.00 | 09/03/2024 | Non-covered Recipient Entity University Of Cincinnati | DS1055-A-J101 | No dispute reported | 06/30/2026 | 1086074136 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $16,000.00 | 09/03/2024 | Non-covered Recipient Entity University Of Cincinnati | DS1055-A-J101 | No dispute reported | 06/30/2026 | 1086074138 |
| Principal investigator 1 | Daiichi Sankyo Company LTD | $23,790.00 | 09/02/2024 | Non-covered Recipient Entity University Of Cincinnati | DS1055-A-J101 | No dispute reported | 06/30/2026 | 1075870269 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $675.00 | 08/01/2024 | Non-covered Recipient Entity University Of Cincinnati | DS1055-A-J101 | No dispute reported | 06/30/2026 | 1086074120 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $945.00 | 08/01/2024 | Non-covered Recipient Entity University Of Cincinnati | DS1055-A-J101 | No dispute reported | 06/30/2026 | 1086074122 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,500.00 | 08/01/2024 | Non-covered Recipient Entity University Of Cincinnati | DS1055-A-J101 | No dispute reported | 06/30/2026 | 1086074124 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,700.00 | 08/01/2024 | Non-covered Recipient Entity University Of Cincinnati | DS1055-A-J101 | No dispute reported | 06/30/2026 | 1086074126 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,700.00 | 08/01/2024 | Non-covered Recipient Entity University Of Cincinnati | DS1055-A-J101 | No dispute reported | 06/30/2026 | 1086074128 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $13,500.00 | 08/01/2024 | Non-covered Recipient Entity University Of Cincinnati | DS1055-A-J101 | No dispute reported | 06/30/2026 | 1086074130 |
| Principal investigator 1 | Daiichi Sankyo Company LTD | $23,020.00 | 07/30/2024 | Non-covered Recipient Entity University Of Cincinnati | DS1055-A-J101 | No dispute reported | 06/30/2026 | 1075870267 |
| Principal investigator 1 | Ares Trading SA | $719.10 | 07/05/2024 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY | An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies | No dispute reported | 06/30/2026 | 1133563052 |
| Principal investigator 1 | Janssen Research & Development, LLC | $184,804.87 | 06/24/2024 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI | Phase II study to evaluate amivantamab in recurrent and metastatic adenoid cystic carcinoma | No dispute reported | 06/30/2026 | 1078999274 |
| Principal investigator 1 | PFIZER INC. | $5,873.00 | 06/05/2024 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI MEDICAL CENTER | A PHASE 1 STUDY OF SGNTGT IN SUBJECTS WITH ADVANCED MALIGNANCIES | No dispute reported | 06/30/2026 | 1130963384 |
| Principal investigator 1 | Ares Trading SA | $1,008.00 | 04/25/2024 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY | An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies | No dispute reported | 06/30/2026 | 1133562988 |
| Principal investigator 1 | Ares Trading SA | $1,008.00 | 04/25/2024 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY | An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies | No dispute reported | 06/30/2026 | 1133563008 |
| Principal investigator 1 | Ares Trading SA | $948.00 | 04/25/2024 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY | An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies | No dispute reported | 06/30/2026 | 1133563014 |
| Principal investigator 1 | Ares Trading SA | $948.00 | 04/25/2024 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY | An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies | No dispute reported | 06/30/2026 | 1133563019 |
| Principal investigator 1 | Ares Trading SA | $948.00 | 04/25/2024 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY | An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies | No dispute reported | 06/30/2026 | 1133563030 |
| Principal investigator 1 | Ares Trading SA | $367.20 | 04/25/2024 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY | An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies | No dispute reported | 06/30/2026 | 1133563043 |
| Principal investigator 1 | Eli Lilly and Company | $201.25 | 04/25/2024 | Covered Recipient Teaching Hospital CHILDRENS HOSPITAL MEDICAL CENTER | A MULTICENTER, RANDOMIZED, OPEN LABEL, PHASE 3 TRIAL COMPARING SELPERCATINIB TO PHYSICIANS CHOICE OF CABOZANTINIB OR VANDETANIB IN PATIENTS WITH PROGRESSIVE, ADVANCED, KINASE INHIBITOR NAIVE, RET MUTANT MEDULLARY THYROID CANCER (LIBRETTO 531) | No dispute reported | 06/30/2026 | 1137349291 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $61,175.63 | 04/22/2024 | Non-covered Recipient Entity University Of Cincinnati | 2016-NIV-0647 Phase II investigation of adjuvant nivolumab after salvage resection in pts treated with definitive chemotherapy and radiation | No dispute reported | 06/30/2026 | 1123480668 |
| Principal investigator 1 | Genentech, Inc. | $1,000.00 | 03/19/2024 | Non-covered Recipient Entity UC HEALTH LLC | PH III open label study atezo vs BSC following adjuvant chemo in stage IB IIIA NSCLC | No dispute reported | 06/30/2026 | 1133461203 |
| Principal investigator 1 | Genentech, Inc. | $6,000.00 | 03/19/2024 | Non-covered Recipient Entity UC HEALTH LLC | PH III open label study atezo vs BSC following adjuvant chemo in stage IB IIIA NSCLC | No dispute reported | 06/30/2026 | 1133461207 |
| Principal investigator 1 | Ares Trading SA | $948.00 | 03/07/2024 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY | An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies | No dispute reported | 06/30/2026 | 1133562841 |
| Principal investigator 1 | Ares Trading SA | $948.00 | 03/07/2024 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY | An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies | No dispute reported | 06/30/2026 | 1133562847 |
| Principal investigator 1 | Ares Trading SA | $948.00 | 03/07/2024 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY | An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies | No dispute reported | 06/30/2026 | 1133562879 |
| Principal investigator 1 | Ares Trading SA | $948.00 | 03/07/2024 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY | An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies | No dispute reported | 06/30/2026 | 1133562885 |
| Principal investigator 1 | Ares Trading SA | $948.00 | 03/07/2024 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY | An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies | No dispute reported | 06/30/2026 | 1133562889 |
| Principal investigator 1 | Ares Trading SA | $948.00 | 03/07/2024 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY | An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies | No dispute reported | 06/30/2026 | 1133562892 |
| Principal investigator 1 | Ares Trading SA | $948.00 | 03/07/2024 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY | An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies | No dispute reported | 06/30/2026 | 1133562899 |
| Principal investigator 1 | Ares Trading SA | $1,008.00 | 03/07/2024 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY | An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies | No dispute reported | 06/30/2026 | 1133562910 |
| Principal investigator 1 | Ares Trading SA | $1,008.00 | 03/07/2024 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY | An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies | No dispute reported | 06/30/2026 | 1133562919 |
| Principal investigator 1 | Ares Trading SA | $813.60 | 03/07/2024 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY | An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies | No dispute reported | 06/30/2026 | 1133562924 |
| Principal investigator 1 | Ares Trading SA | $1,008.00 | 03/07/2024 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY | An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies | No dispute reported | 06/30/2026 | 1133562948 |
| Principal investigator 1 | Ares Trading SA | $1,008.00 | 03/07/2024 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY | An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies | No dispute reported | 06/30/2026 | 1133562954 |
| Principal investigator 1 | Ares Trading SA | $1,008.00 | 03/07/2024 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY | An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies | No dispute reported | 06/30/2026 | 1133562958 |
| Principal investigator 1 | Ares Trading SA | $1,008.00 | 03/07/2024 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY | An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies | No dispute reported | 06/30/2026 | 1133562974 |
| Principal investigator 1 | Ares Trading SA | $948.00 | 03/07/2024 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY | An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies | No dispute reported | 06/30/2026 | 1133562979 |
| Principal investigator 1 | Ares Trading SA | $948.00 | 03/07/2024 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY | An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies | No dispute reported | 06/30/2026 | 1133562982 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $144,083.28 | 02/27/2024 | Non-covered Recipient Entity University Of Cincinnati | PhI/II TIGIT BiSpec combo (Nivo/NG CTLA4) safety & NSCLC expansion - A Phase 1b/2 Study of BMS-986442 in Combination with Nivolumab or Nivolumab and Chemotherapies in Participants with Advanced Solid Tumors and Non-small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1123480682 |
| Principal investigator 1 | Eli Lilly and Company | $25,584.00 | 02/13/2024 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI PHYSICIANS | A MULTICENTER, RANDOMIZED, OPEN LABEL, PHASE 3 TRIAL COMPARING SELPERCATINIB TO PHYSICIANS CHOICE OF CABOZANTINIB OR VANDETANIB IN PATIENTS WITH PROGRESSIVE, ADVANCED, KINASE INHIBITOR NAIVE, RET MUTANT MEDULLARY THYROID CANCER (LIBRETTO 531) | No dispute reported | 06/30/2026 | 1137368746 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $115,144.00 | 02/08/2024 | Non-covered Recipient Entity UC HEALTHCARE SYSTEM | An Open-label, Phase II Study of Durvalumab (MEDI4736) in combination with Cetuximab in Previously Treated Metastatic Head and Neck Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1110835855 |
| Principal investigator 1 | AstraZeneca UK Limited | $21,125.00 | 01/29/2024 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY LLC | A Phase 1b 2 Open Label Multicentre Study Assessing the Safety Tolerability Pharmacokinetics and Preliminary Anti tumour Activity of MEDI4736 in Combination With AZD9150 or AZD5069 in Patients With Advanced Solid Malignancies and Subsequently Comparing AZD9150 and AZD5069 Both as Monotherapy and in Combination With MEDI4736 as Second Line Treatment in Patients With Recurrent and or Metastatic Squamous Cell Carcinoma of the Head and Neck | No dispute reported | 06/30/2026 | 1110844320 |
| Principal investigator 1 | Ares Trading SA | $948.00 | 01/03/2024 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY | An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies | No dispute reported | 06/30/2026 | 1133562852 |
| Principal investigator 1 | Ares Trading SA | $556.80 | 01/03/2024 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY | An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies | No dispute reported | 06/30/2026 | 1133562869 |
| Principal investigator 1 | Ares Trading SA | $1,008.00 | 01/03/2024 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY | An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies | No dispute reported | 06/30/2026 | 1133562929 |
| Principal investigator 1 | Ares Trading SA | $1,008.00 | 01/03/2024 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY | An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies | No dispute reported | 06/30/2026 | 1133562942 |